Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052974 | 0.84 | GPR55 (0.40) | GPR55ELANERARARARBRARG | |
| SCHEMBL21487490 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL4522338 | 0.73 | LMNA (0.34) | LMNA | |
| SCHEMBL12032783 | 0.72 | GPR55 (0.35) | GPR55ELANELMNA | |
| SCHEMBL6127938 | 0.69 | GPR55 (0.37) | GPR55CNR2 | |
| SCHEMBL29631689 | 0.66 | GPR55 (0.47) | GPR55RARARARBRARGCNR2 | |
| SCHEMBL1821982 | 0.64 | ELANE (0.41) | ELANE | |
| SCHEMBL9147142 | 0.64 | KDM4E (0.35) | ELANE | |
| SCHEMBL11094361 | 0.64 | NUDT1 (0.32) | — | |
| SCHEMBL13193188 | 0.63 | CCR1 (0.37) | GPR55LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | GPR55 3572/4885ELANE 1356/4885RARA 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.